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NEUROCYSTICERCOSIS IN ASPLENIC PATIENT, 
CASE REPORT
NEUROCISTICERCOSE EM PACIENTE ASPLÊNICO, RELATO DO CASO
Ericson Dametto1, Sinandra Zuffo2, Michal Juhas1, Manoj Kumar Malic1
ABSTRACT 
Neurocysticercosis is an important cause of neurologic and psychia-
tric disorders; it is a frequent etiology for acquired epilepsy worldwi-
de. The parasitic infection of Taenia solium (including larval dissemi-
nation to the nervous system) can be avoided by effective means of 
prevention. Nonetheless, this disease remains endemic in many re-
gions of the world. 
To demonstrate the importance of prophylaxis this paper reports the 
case of a patient without spleen, who was treated for neurocysticer-
cosis manifested by epilepsy. In twenty years of follow up, the patient 
did not experience a repeat occurrence of neurocysticercosis, despite 
of immunological impairment (absence of spleen) and environmental 
exposure (living in an endemic area).  
Prevention was guided by a regular use of anthelmintic (Albendazole) 
and health education.  
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RESUMO
Neurocisticercose é uma importante causa de doenças neurológicas 
e psiquiátricas, é uma frequente etiologia de epilepsia adquirida, no 
mundo. A infecção parasitária da Taenia solium (incluindo a dissemi-
nação das larvas para o sistema nervoso) pode ser evitada por meios 
eficazes de prevenção; no entanto, esta enfermidade ainda é endê-
mica em muitas regiões do mundo.
Para demonstrar a importância da profilaxia relata-se o caso de um 
paciente sem baço, o qual foi tratado para a neurocisticercose mani-
festada por epilepsia. Em vinte anos de seguimento, o paciente não 
repetiu a ocorrência de neurocisticercose, apesar de dano imunoló-
gico (ausência de baço) e exposição ambiental (habitação em área 
endêmica).
A prevenção foi guiada pelo uso regular de anti-helmíntico (Albenda-
zole) e medidas educativas em saúde.
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REVIEW
Neurocysticercosis is considered the leading 
cause of preventable neurological diseases in the world. 
Endemic areas include South and Central America, Asia, 
Sub-Saharan Africa, and India. It is also emerging in 
non-endemic areas due to migration and travelers, particu-
larly in European countries, the United States of America, 
and Canada.
In Brazil, epidemiological studies consider the 
prevalence of the disease as underestimated, reporting in-
cidence of 1.5% in autopsies and 3% in clinical trials.(1)
Case reports of neurocysticercosis in the inter-
national literature are more common than in Brazil. How-
ever, Brazilian publications add both quality and rarity to 
the body of literature. For example:
a)  Rare presentations: Bruns syndrome, i.e., epi-
sodic hydrocephalus with cyst movement in brain ven-
tricles,(2) frontotemporal dementia with mutism,(3) spastic 
paraplegia,(4) seizures and psychiatric manifestations of 
temporal lobe,(5) trigeminal neuralgia,(6) Lennox-Gastaut 
syndrome,(7) and presented with giant multiple cysts.(8) (9)
b)  Atypical locations of cysts: brainstem (occur-
ring in 8% of cases),(10) intramedullary,(11) (occurring in 1.2 
to 5.8% of cases).(12)
 Although appropriate prophylaxis for neurocys-
ticercosis exists, the disease remains as a common cause 
of epilepsy and is also associated with a variety of sensory 
and motor deficits. Estimated 7.6 million cases of epilep-
sy are associated with neurocysticercosis, considering the 
world population.(13)
In studies of prophylaxis the use of 400 mg Alben-
dazole for three consecutive days, 2 times a year, has been 
demonstrated to produce significant reduction of taeniasis 
(and other helminthiasis)  when administered to partici-
pants who are over six years old,  who are not pregnant or 
breastfeeding, and who do not suffer from acute diseases.(14)
Taenia solium eggs can be transmitted between 
humans. Such interpersonal transmission can lead to 
neurocysticercosis.
Animals, particularly pigs, are intermediate hosts, 
because they harbor the parasite in its larval forms. Hu-
mans are the definitive hosts, because they house the 
Taenia solium in its adult form. The adult worm is able to 
disseminate thousands of fertilized eggs daily.
The eggs can be ingested in water or on con-
taminated food. The eggs hatch in the human intestine 
after exposure to bile and pancreatic juice. The larvae 
(metacestodae) become mature in the digestive tract, caus-
ing taeniasis. The larvae can also spread throughout the 
bloodstream, causing cysticercosis in various organs such 
as eyes, brain, muscles, subcutaneous tissue, etc. Another 
route of contamination is by ingestion of undercooked 
pork containing the living larvae.(15)
Contamination can be prevented by thorough 
cooking of meat, sanitation of fresh foods (such as fruits, 
vegetables…), washing of hands, as well as by animal’s 
health inspection.
The immune system, in order to combat the 
metacestodae, recruits the participation of several cells 
(eosinophils, lymphocytes, monocytes, plasma cells, 
macrophages...) and chemical mediators (lymphokines, 
interferons, tumor necrosis factor...).(16)
In the brain, the formation of granulomas around 
the cysts illustrates the importance of these cellular mech-
anisms in combating neurocysticercosis. Granulomas are 
formed by macrophages and their derived cells (giant cells, 
epithelioid). Other defensive mechanisms include the peri-
vascular mononuclear infiltration, the fibroblast multipli-
cation, and the microglia proliferation. The phagocytic ca-
pacity of macrophages and microglial cells highlights the 
participation of reticuloendothelial system (mononuclear 
phagocyte system) in the defense against neurocysticerco-
sis. (17)
The spleen is the largest of the lymph organs and 
part of the reticuloendothelial system. Therefore, it forms 
an integral part in the prevention of neurocysticercosis in-
fections.
Spleen is more efficient than liver in the removal of 
non-opsonized bacteria and encapsulated organisms. En-
capsulated pathogens such as Streptococcus pneumoniae, 
Neisseria meningitidis, or Haemophilus influenzae type B 
can cause severe infections in post-splenectomy patients. 
The spleen not only purifies blood from fungi, viruses, and 
foreign bodies but also participates in hematopoiesis and 
immunoglobulin synthesis.(18) (19)
The literature proposes that the absence of spleen 
weakens the mononuclear phagocyte system. This evi-
dence suggests that asplenia may hinder successful pre-
vention of long-term neurocysticercosis recurrence in 
spenectomized patients and inhabitants of endemic areas.
OBJECTIVE
The objective of this paper is to report both the 
follow-up of a patient with neurocysticercosis and asplenia 
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as well as to describe the prophylaxis against helminthiasis 
used in this case.
METHODOLOGY
In this case report, we present the evolution of 
neurocysticercosis in a splenectomized patient, observing 
the patient twice a year for over 20 years.
CASE REPORT
The patient was referred to neurology department 
of Our Lady of Conception Hospital in Porto Alegre, Bra-
zil, to investigate epilepsy. The patient was 24 years old, 
male, with professional activities in pig farming, from a 
rural area, where several cases of neurocysticercosis have 
occurred.
The history of the patient revealed seizures begin-
ning at 21 years of age. The crises were characterized as 
tonic-clonic and occurred on a monthly basis; phenobarbi-
tal could not control the seizures. Episodes of holocranial 
headache emerged at the same time as the seizures.
The patient reported splenectomy surgery at 11 
years of age, due to a physical trauma caused by a fall from 
height. Other conditions such as drug addiction, AIDS, or 
head trauma were excluded. General clinical and labora-
tory examinations revealed no abnormalities. Neurologic-
al examination found no motor or sensory impairments. 
Electroencephalography showed bursts of sharp and poly-
spike waves generalized with asymmetric amplitude.
Computed tomography (CT) of the head docu-
mented multiple cystic lesions forming a “Swiss cheese 
pattern”, which refers to the significant amount of dissem-
inated cysts in the brain parenchyma. The multiple lesions 
had ovoid shapes with dimensions of approximately 5-10 
mm, filled with liquid. Within a few cysts, visible scolices 
were present with a characteristic “comma” shape and al-
tered intensity compared to the vesicular fluid. The cysts 
were in various stages of evolution, predominantly in stage 
I (minimal tissue reactions or absent) and II (with perile-
sional edema). CT findings characterized the neurocystic-
ercosis lesions.
Based on the revised diagnostic criteria,(20) the 
case met: a) an absolute diagnostic criterion; b) a major 
criterion; c) as well as minor and epidemiological criteria 
(Table 1). This set established definitive diagnosis.
We treated parenchymatous neurocysticerco-
sis with: a) use of antiparasitic drugs, b) management 
of seizures, and c) management of cerebral edema. 
The patient was hospitalized at the hospital of origin; we 
prescribed Albendazole 5 mg/kg/ day for 4 weeks; and 
Phenobarbital 100 mg /day continuous, and Dexametha-
sone 12 mg/day for 1 week; in consensus with the treat-
ment recommendations for neurocysticercosis.(21) 
The treatment maintained the initial Phenobarbital 
monotherapy because the cause of the uncontrolled sei-
zures lied in the  brain edema controlled by corticosteroid.
After treatment, seizures had a complete 
remission. The follow-up CT, after one year of treatment, 
showed regression of lesions to calcification, reduction 
in the diameter of the cysts from 5 to 1 mm on average, 
perilesional resolution of edema, absence of ventricular 
dilatation, or subsequent gliosis.
DISCUSSION
Patient’s origin from an endemic area and the pro-
fessional activity in swine farming were significant in the 
case reported; however, neurocysticercoses are known to 
occur also in in non-endemic areas among migrants and 
travelers.
The patient’s prior splenectomy has led to prophy-
Table 1. Diagnostic criteria
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lactic care that included the use of 400 mg Albendazole 
every 6 months. Also, other means of prophylaxis were 
included such as thorough cooking of pork, evaluating the 
origin of fruits and vegetables, and proper hygiene and dis-
eases prevention practices.(22)
In the following 20 years, the patient 
did not develop subsequent neurocysticercosis. 
 An interesting finding was the occurrence of an-
other parasitic disease, the ganglionic form of toxoplasmo-
sis, twenty years after neurocysticercosis hospitalization. 
 The literature documents in mice experiments that 
the Taenia species inhibits certain defense mechanisms of 
spleen cells. Infection by Taenia taeniaeformis decreases 
the ability of spleen cells to respond to the mitotic factor 
concavaline A.(23) Similar effect occurs in toxoplasmosis. 
Toxoplasma gondii infections in mice inhibit mitotic effect 
of concavaline A on T cells in the spleen;(24) toxoplasma 
decreases also the production of interferon gamma and 
other cytokines in spleen cells.(25) Similarities between 
these two parasitic infections highlight the importance of 
macrophagic defence mechanisms and need for prophy-
laxis and adequate follow-up in asplenic individuals.
CONCLUSIONS
Treatment and prophylaxis of neurocysticercosis 
were effective, despite of the splenectomy factor.
This case report of neurocysticercosis is associa-
ted with asplenia, which brings attention to the role of mo-
nonuclear phagocyte system in the defenses against neuro-
cysticercosis and toxoplasmosis. 
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